Canadian Journal of Gastroenterology and Hepatology

Canadian Journal of Gastroenterology and Hepatology / 2003 / Article

Open Access

Volume 17 |Article ID 714124 | https://doi.org/10.1155/2003/714124

Alex Ford, Paul Moayyedi, "How Can the Current Strategies for Helicobacter pylori Eradication Therapy be Improved?", Canadian Journal of Gastroenterology and Hepatology, vol. 17, Article ID 714124, 5 pages, 2003. https://doi.org/10.1155/2003/714124

How Can the Current Strategies for Helicobacter pylori Eradication Therapy be Improved?

Abstract

BACKGROUND: The use of Helicobacter pylori eradication therapy is advocated in an increasing variety of situations. It is therefore important to optimise current strategies to eradicate H pylori infectionOBJECTIVES: To define the optimum dosage, drugs and duration of proton pump inhibitor (PPI) triple therapy.METHODS: A review of the literature was performed to identify randomized controlled trials and systematic reviews addressing these issues.RESULTS: In PPI, amoxicillin and clarithromycin (PAC) based regimens, twice daily PPI gave optimal eradication rates (relative risk reduction [RRR] compared with once daily = 7%; 95% CI 2% to 12%), but in PPI, clarithromycin and metronidazole (PCM) based regimens there was no difference (RRR = 2%; 95% CI –7% to 10%). Omeprazole and lansoprazole- containing triple therapies achieved similar eradication rates, but rabeprazole appeared superior to omeprazole (RRR = 8%; 95% CI 2% to 14%). The optimum clarithromycin dose in a PAC regimen was 500 mg twice daily (RRR = 11%; 95% CI = 3% to 18%), but 250mg twice daily in a PCM regimen (RRR = 2%; 95% CI –4% to 7%). Eradication rates were lower with a seven day regimen compared with fourteen (RRR = 12%; 95% CI 7% to 17%). Overall there was no difference between a PAC and a PCM regimen (RRR = 0%; 95% CI –3% to 3%).CONCLUSIONS: PAC and PCM regimens are equally effective if used optimally, though PCM is cheaper. The eradication regimen and its duration should be tailored according to the clinical situation.

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views83
Downloads274
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.